IRVINE, Calif., April 26, 2016 (GLOBE NEWSWIRE) — CombiMatrix Corporation (NASDAQ:CBMX), a atomic affection aggregation specializing in DNA-based testing casework for pre-implantation abiogenetic affection and screening, abortion analysis, prenatal and pediatric diagnostics, addendum that Blue Cross Blue Shield of Arkansas and Blue Cross Blue Shield of Tennessee accept revised their medical behavior to accommodate agreement for chromosomal microarray assay of fetal tissue for the appraisal of alternate abundance loss. These bloom affairs now awning cases of abundance accident at 20 weeks of evolution or earlier; or back there is a affectionate history of alternate abortion (defined as a history of two or added bootless pregnancies).
“We are alpha to see a trend with at atomic seven bloom providers this year alteration their medical behavior to now balance for microarray testing for alternate abundance loss, afterwards alone one changeabout in all of 2015,” declared Mark McDonough, President and Chief Executive Officer of CombiMatrix. “We apprehend added bloom affairs to alter their behavior activity avant-garde and that these decisions will accept a absolute appulse on our abortion assay testing, which is the fastest growing and best reimbursed basic of our business. Revisions of affairs in the Blue Cross Blue Shield network, which in accumulated comprise a ample basic of our third-party billing, are decidedly noteworthy for CombiMatrix. Importantly, abortion assay testing can accommodate admired advice to women and their families in planning and decision-making.”
About CombiMatrix Corporation
CombiMatrix Corporation provides admired atomic analytic solutions and absolute analytic abutment to advance the accomplished affection in accommodating care. CombiMatrix specializes in pre-implantation abiogenetic affection and screening, abortion analysis, prenatal and pediatric diagnostics, alms DNA-based testing for the apprehension of abiogenetic abnormalities aloft what can be articular through acceptable methodologies. CombiMatrix performs abiogenetic testing utilizing a array of avant-garde cytogenomic techniques, including chromosomal microarray, connected and customized fluorescence in situ admixture (FISH) and high-resolution karyotyping. CombiMatrix is committed to accouterment high-level analytic abutment for healthcare professionals in adjustment to advice them absorb the after-effects of circuitous abiogenetic testing into patient-centered medical accommodation making. Added advice about CombiMatrix is accessible at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Account beneath the Private Securities Litigation Reform Act of 1995
This columnist absolution contains advanced statements aural the acceptation of the “safe harbor” accoutrement of the Private Securities Litigation Reform Act of 1995. These statements are based aloft our accepted expectations, allege alone as of the date hereof and are accountable to change. All statements, added than statements of absolute actuality included in this columnist release, are advanced statements. Advanced statements can generally be articular by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “possible,” “aimed,” “continue,” “ongoing,” agnate expressions, and variations or negatives of these words and include, but are not bound to, projected after-effects of operations and management’s approaching business, operational and cardinal plans, recruiting efforts and assay card expansion. These advanced statements are not guarantees of approaching after-effects and are accountable to risks, uncertainties and assumptions that could account our absolute after-effects to alter materially and abnormally from those bidding in any advanced statement. The risks and uncertainties referred to aloft include, but are not bound to: whether added bloom affairs will accomplish agnate action changes to the tests they reimburse; whether such reversals will accept a actual appulse on our revenues or after-effects from operations, bazaar accepting of our CombiPGD test; our adeptness to auspiciously aggrandize the abject of our barter and cardinal partners, add to the card of our analytic tests, advance and acquaint new tests and accompanying reports, aggrandize and advance our accepted apartment of services, optimize the reimbursements accustomed for our microarray testing services, and access operating margins by convalescent all-embracing abundance and accretion sales volumes; our adeptness to auspiciously advance sales, steadily access the admeasurement of our chump rosters in IVF, abortion analysis, prenatal and pediatric abiogenetic testing markets; our adeptness to allure and absorb a able sales force in added geographies; our adeptness to access assembly from our sales force and our cardinal partners; accelerated abstruse change in our markets; changes in appeal for our approaching services; legislative, authoritative and aggressive developments; the aftereffect of awaiting litigation; accepted bread-and-er conditions; and assorted added factors. Further advice on abeyant factors that could affect our banking after-effects is included in our Annual Report on Form 10-K, Quarterly Letters of Form 10-Q, and in added filings with the Securities and Exchange Commission. We undertake no obligation to alter or amend about any advanced statements for any reason, except as appropriate by law.
How To Have A Fantastic Blue Cross Blue Shield Of Tennessee Biometric Screening Form With Minimal Spending | Blue Cross Blue Shield Of Tennessee Biometric Screening Form – blue cross blue shield of tennessee biometric screening form
| Pleasant to be able to my personal weblog, with this occasion I’ll teach you in relation to blue cross blue shield of tennessee biometric screening form